We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Revised Guidance on HCV Drug Development Tweaks Trial Standards
Revised Guidance on HCV Drug Development Tweaks Trial Standards
Companies developing direct-acting antiviral hepatitis C drugs should factor in interferon treatment when designing clinical trials, the FDA said Tuesday.